management of advanced prostate carcinoma
TRANSCRIPT
![Page 1: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/1.jpg)
DISCUSS THE MANAGEMENT OF A 65 YEAR OLD POLITICIAN WITH
ADVANCED PROSTATE CARCINOMA
DR BASSEY, A. E.
![Page 2: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/2.jpg)
OUTLINE• INTRODUCTION
• DEFINITION• EPIDEMIOLOGY
• RELEVANT ANATOMY• RISK FACTORS• PATHOGENESIS
• PATHOLOGY• SPREAD• STAGING/GRADING
• MANAGEMENT• HISTORY• EXAMINATION• INVESTIGATION• TREATMENT• COMPLICATIONS
• FOLLOW-UP/PROGNOSIS• PREVENTION• CURRENT TRENDS• CONCLUSION• REFERENCES
![Page 3: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/3.jpg)
INTRODUCTION
• PROSTATE CARCINOMA IS A MALIGNANT PROLIFERATION OF THE EPITHELIAL CELLS OF THE GLANDULAR COMPONENT OF THE PROSTATE GLAND
![Page 4: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/4.jpg)
EPIDEMIOLOGY
• MOST COMMONLY DIAGNOSED CANCER IN NIGERIAN MEN1
• IT IS THE LEADING CAUSE OF MALE CANCER DEATHS
• INCIDENCE IS ON THE RISE• POST-MORTEM SPECIMENS REVEAL THE
DISEASE IN 14% OF MEN >50YRS & 80% >70YRS
![Page 5: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/5.jpg)
RELEVANT ANATOMY
![Page 6: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/6.jpg)
RISK FACTORS• AGE: why? *in older men, though testosterone levels fall, the prostate receptors
become more sensitive to androgen *with aging the estrogen level rises and this increases prostate sensitivity to androgen as well
• HORMONAL FACTORS: why? *in men castrated before puberty there’s almost no CaP
• RACE: *in africans testosterone is higher than other races *5-AR levels is also higher so DHT is higher *black skin reduces UV entry therefore vit D production is less. Vit D is protective.
• GENETIC FACTORS: *implicated genes are HPCancer gene 1, HPCancer gene 2, BRCA-2
• HIGH FAT DIET: *due to increased peripheral conversion in adipose
• SMOKING: cadmium exposure
![Page 7: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/7.jpg)
PATHOGENESIS - PATHOLOGY
• IT IS AN ADENOCARCINOMA• TYPES INCLUDE:
• ORDINARY ADENOCARCINOMA• MUCINOUS ADENOCARCINOMA• DUCTAL AGGRESSIVE TYPE• NEUROENDOCRINE TUMOUR• SMALL CELL CARCINOMA
![Page 8: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/8.jpg)
PATHOGENESIS - SPREAD• LOCAL
• PROSTATIC URETHRA• BLADDER BASE• EXTERNAL URETHRAL SPHINCTER• SEMINAL VESICLES• PELVIC NERVES• RECTUM
• HAEMATOGENOUS• BONES• LIVER • LUNGS • BRAIN
• LYMPHATIC SPREAD
![Page 9: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/9.jpg)
STAGING
![Page 10: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/10.jpg)
STAGING
• ADVANCED PROSTATE CARCINOMA IS THEREFORE2:
• T3 OR T4, N0, M0• N1, ANY T, ANY M• M1, ANY T, ANY N
![Page 11: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/11.jpg)
TUMOUR GRADING
![Page 12: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/12.jpg)
MANAGEMENT - HISTORY
• LUTS
• LOCALLY ADVANCED DISEASE
• METASTATIC DISEASE
• CO-MORBIDITIES
![Page 13: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/13.jpg)
MANAGEMENT - EXAMINATION• GENERAL – CACHEXIA, PALLOR, JAUNDICE,
LYMPHADENOPATYHY, PEDAL OEDEMA• ABDOMEN – DISTENDED BLADDER, BALLOTABLE
KIDNEYS, HEPATOMEGALY, PALPABLE MASSES PER ABDOMEN
• DRE • NEUROLOGICAL EXAM – PARAPARESIS,
BULBOCAVERNOSUS REFLEX, SENSORY LEVEL• MUSCULOSKELETAL EXAM – PATHOLOGICAL #• CHEST – RIB PAIN• CVS – HYPERTENSION, ARRHYTHMIAS
![Page 14: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/14.jpg)
MANAGEMENT - INVESTIGATION• TO CONFIRM DGX
• PSA : low in *SqCCa*neuroendocrine tumor*anaplastic Ca• TRUS/DIGITALLY-GUIDED BIOPSY
• TO DETERMINE EXTENT OF DISEASE• TRUS PROSTATE:*enlarged prostate*hypoechoic in peripheral
zones*distorted capsule*enlarged seminal vesicles*degree of local infiltration*bladder findings
• CT/MRI PELVIS• XRAY SPINE (deposits occur at pedicles becos vertebral plexus runs
along it)• XRAY PELVIS• CXR (BONE SCINTIGRAPHY used in early tumors to r/o bone deposits)• ABDOMINOPELVIC USS :*upper tract dilatation*liver deposits
*ascites*LNs• LFT• CT BRAIN• IVU +/- URETHROCYSTOSCOPY IF THERE’S HEMATURIA
![Page 15: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/15.jpg)
MANAGEMENT - INVESTIGATION
• TO AID MGT• FBC• E/U/CR• FBS• URINALYSIS• URINE M/C/S
![Page 16: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/16.jpg)
MANAGEMENT -TREATMENT• THE AIM IS PALLIATIVE AND APPROACH IS
MULTIDISCIPLINARY – SURGEON, ONCOLOGIST, PHYSICIAN, PHYSIOTHERAPIST, PSYCHOLOGIST, RELATIVES
• CORRECT DERANGEMEN• ANAEMIA• SEVERE HAEMATURIA (HAEMATURIA COMMONER IN BPH)• ACUTE URINARY RETENTION• CLOT RETENTION• UTI
![Page 17: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/17.jpg)
MANAGEMENT - TREATMENT
• THE CRUX OF TREATMENT IS HORMONAL MANIPULATION
• ANTIANDROGEN + LHRH AGONIST• ANTIANDROGEN + BILATERAL ORCHIDECTOMY• ANTIANDROGEN + DIETHYLSTILBOESTROL
• PATIENT COUNSELLING• DIAGNOSIS• TREATMENT OPTIONS• COMPLICATIONS OF TREATMENT• PROGNOSIS
![Page 18: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/18.jpg)
MANAGEMENT - TREATMENT
• FOR LOCALLY ADVANCED, NEO-ADJUVANT HORMONAL THERAPY OR NEO-ADJUVANT RADIOTHERAPY CAN BE DONE FOLLOWED BY RADICAL PROSTATECTOMY.
• EXCLUSION CRITERIA - *PTS WITH <10YRS LIFE EXPECTANCY *PTS WITH SEVERE COMORBIDITY
• SUCCESS OF SURGERY IS PSA NADIR <0.2ng/ml
![Page 19: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/19.jpg)
LHRH AGONIST BILATERAL ORCHIDECTOMY
1. COSTLY2. COMPLIANCE PROBLEMS3. FLARE PHENOMENON4. ESCAPE PHENOMENON5. BREAKTHROUGH PHENOMENON
LHRH AGONIST WORKS BY: *NEGATIVE FEEDBACK *PLUMMETING EFFECT
1. CHEAP2. NO COMPLIANCE PROBLEMS3. PSYCHO EFFECTS OF CASTRATION
MONOTHERAPY MAB
1. DECREASED COMPLICATIONS2. DECREASED COST
1. PREFERABLE FOR THOSE WITH POOR PROGNOSIS AT THE OUTSET
![Page 20: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/20.jpg)
MANAGEMENT - TREATMENT
• INTERMITTENT HORMONAL THERAPY (DONE TO SLOW PROGRESSION TO HORMONE-RESISTANT STATE
• MAB GIVEN FOR 36 WEEKS AND TREATMENT STOPPED• PSA NADIR NOTED• TREATMENT RESUMED AFTER 32 WEEKS• HOWEVER, IF IN THE INTERVAL PSA RISES ABOVE
20NG/ML OR THERE’S A DOUBLING OF NADIR PSA TREATMENT IS RESUMED
![Page 21: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/21.jpg)
MANAGEMENT - TREATMENT• PAIN CONTROL
• MAB• NARCOTICS• RADIOTHERAPY
• URINE RETENTION• MAB• CHANNEL TURP• RADIOTHERAPY• STENT• CHRONIC INDWELLING CATHETER• CISC
• BONE DESTRUCTION• BISPHOSPHONATES• RADIOTHERAPY
• URETERIC OBSTRUCTION 2o LNs• URETERIC STENT• NEPHROSTOMY
• PHYSIOTHERAPY
![Page 22: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/22.jpg)
MANAGEMENT - COMPLICATIONS• URINE RETENTION• CLOT RETENTION• RENAL INSUFFICIENCY• URINARY INCONTINENCE• PARAPLEGIA• ERECTILE DYSFUNCTION• PATHOLOGIC FRACTURES• DECREASED LIBIDO• DEPRESSION
![Page 23: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/23.jpg)
FOLLOW-UP/PROGNOSIS
• FOLLOW UP – THIS IS FOR LIFE• HISTORY• EXAMINATION• DRE• SERUM PSA, PSA DENSITY, PSA VELOCITY
• PROGNOSIS• INDICATORS ARE – GLEASON SCORE, TNM STAGE,
HISTOLOGIC TYPE, AGE AT DIAGNOSIS• VIRTUALLY ALL ADVANCED PROSTATE CARCINOMA
PROGRESS TO A HORMONE-RESISTANT STATE AFTER 12-18MTHS OF TREATMENT BEYOND WHICH MEDIAN SURVIVAL IS 2-3 YEARS (BADOE – 24-38WKS i.e 6-9MTHS)
![Page 24: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/24.jpg)
PREVENTION
• PUBLIC AWARENESS• SCREENING – EARLY DIAGNOSIS = POSSIBLE
CURE• AVOIDANCE OF KNOWN RISK FACTORS –
SMOKING, HIGH FAT DIET
![Page 25: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/25.jpg)
CURRENT/FUTURE TRENDS
• USE OF 5-ALPHA REDUCTASE INHIBITORS• TARGETED THERAPY
• ANDROGEN SYNTHESIS INHIBITOR – ABIRATERONE ACETATE - DROPS TESTOSTERONE TO LEVELS LOWER THAN ANY PRESENT FORM OF TREATMENT3
• LHRH ANTAGONISTS – DEGARELIX – AVOIDS FLARE PHENOMENON4
• PSMA-ADC: ANTIBODY + MONOMETHYL AURISTATIN E5 (DISRUPTS TUBULINS)
![Page 26: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/26.jpg)
CONCLUSION
• DUE TO HIGH PREVALENCE AND RISING INCIDENCE OF CARCINOMA OF THE PROSTATE IN OUR ENVIRONMENT, THE NEED FOR FORMAL SCREENING POLICY AND EFFORTS TOWARD PREVENTION AND EARLY DIAGNOSIS CANNOT BE OVER-EMPHASISED, DESPITE INSPIRING ADVANCES IN MOLECULAR CHARACTER AND TREATMENT OF THIS DISEASE.
![Page 27: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/27.jpg)
THANK YOU
![Page 28: Management of advanced prostate carcinoma](https://reader036.vdocument.in/reader036/viewer/2022062703/5552b0f6b4c905d9508b4e81/html5/thumbnails/28.jpg)
REFERENCES1. Prevalence and characteristics of prostate cancer among
participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. doi:10.11604/pamj.2013.15.129.2489
2. http://www.cancerresearchuk.org/cancer-help/type/prostate-cancer/treatment/the-stages-of-prostate-cancer
3. http://www.cancer.gov/cancertopics/understandingcancer/targetedtherapies/prostatecancer_htmlcourse/page2
4. The role of LHRH antagonists in the treatment of prostate cancer. http://www.ncbi.nlm.nih.gov/pubmed/19626830#
5. http://www.ecco-org.eu/Global/News/ENA-2012-PR/2012/11/8_11-New-targeted-therapy-for-advanced-prostate-cancer.aspx
6. http://emedicine.medscape.com/article/1967731-overview7. PRINCIPLES & PRACTICE OF SURGERY INCLUDING PATHOLOGYIN
THE TROPICS, BADOE ET AL, pp 939 - 952